1 Matching Annotations
  1. Last 7 days
    1. #10PCC(11)15c.340+682T>CNANoc.482G>A p.R161QPosDecreaseIncreasePathogenic

      PatientID: 10

      KindredID: 10

      Case: Sex Unknown, 26Y0M, Ethnicity Unknown

      DiseaseAssertion: Pheochromocytoma

      FamilyInfo: N/A - not stated

      CasePresentingHPOs: HP:0002666 (pheochromocytoma)

      CaseHPOFreeText: A pheochromocytoma (PCC) diagnosed first at 11Y was found, with follow up of a 15 year duration.

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: N/A

      PreviouslyPublished: N/A

      SupplementalData: Yes

      Variant: c.340+682T>C

      LegacyVariant: N/A

      CaseProblemVariantFreeText: N/A

      ClinVarID: 964770 https://www.ncbi.nlm.nih.gov/clinvar/variation/964770

      CAID: N/A

      gnomAD: N/A

      VariantEvidence: Tumor analysis was performed since there was a paraffin embedded sample. Patient 10 did not have loss of heterozygosity, but was found to have a somatic variant in the exon 3 of VHL (c.482G>A; p.Arg161Gln). This was the only patient observed to have a cluster of tumor cells with a positive membranous CA9 immunostaining, this can be seen in VHL-related PPGL. CA9 is a protein reported to influence regulation cell proliferation and tumor progression and is known to be expressed at the membrane of tumour cells in the case of VHL inactivation can be seen in VHL-related PPGL. Subsequently as expected, the PPGL of patient 10 had a significantly low expression of VHL E1-E1' mRNA VHL and PNMT mRNA compared to VHL-tumours used as controls. This suggests that the two VHL variants change the VHL mRNA splicing.

      MutationType: splice_site_variant

      CivicName: Splice Site (c.340+682T>C); intron_variant

      MultipleGeneVariants: Somatic, VHL, c.482G>A (p.Arg161Gln)